Alerts will be sent to your verified email
Verify EmailPPLPHARMA
|
Piramal Pharma
|
Cohance Lifesciences
|
Suven Life Sciences
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Pharmaceuticals
|
|||
|
Domestic Sales Growth - YoY
|
15.43 % | n/a | n/a |
|
R&D as a % of Total Sales
|
0.14 % | 4.19 % | 2132.75 % |
|
Financials
|
|||
|
5 yr Average ROE
|
1.39 % | 22.91 % | 0.0 |
|
5yr average Equity Multiplier
|
1.99 | 1.35 | 1.55 |
|
5yr Average Asset Turnover Ratio
|
0.53 | 0.56 | 0.05 |
|
5yr Avg Net Profit Margin
|
0.13 % | 30.38 % | -1150.51 % |
|
Price to Book
|
2.93 | 4.32 | 15.6 |
|
P/E
|
0.0 | 94.21 | 0.0 |
|
5yr Avg Cash Conversion Cycle
|
-54.64 Days | 49.95 Days | 97.84 Days |
|
Inventory Days
|
75.95 Days | 74.21 Days | 10.88 Days |
|
Days Receivable
|
78.2 Days | 63.71 Days | 71.91 Days |
|
Days Payable
|
172.59 Days | 80.35 Days | 0.0 |
|
5yr Average Interest Coverage Ratio
|
1.59 | 49.87 | -373.47 |
|
5yr Avg ROCE
|
4.67 % | 27.5 % | -82.34 % |
|
5yr Avg Operating Profit Margin
|
12.64 % | 40.14 % | -1227.3 % |
|
5 yr average Debt to Equity
|
0.65 | 0.06 | 0.0 |
|
5yr CAGR Net Profit
|
n/a | -5.86 % | 17.38 % |
|
5yr Average Return on Assets
|
0.1 % | 17.54 % | -54.63 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
34.8 % | 57.49 % | 70.08 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
0.01 % | -2.51 % | 0.51 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
12.27 % | 10.01 % | 0.0 |
|
Piramal Pharma
|
Cohance Lifesciences
|
Suven Life Sciences
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
|
Services Break-Up
|
Services Break-Up
|
-
|
-
|